Kymera Therapeutics (NASDAQ:KYMR) Price Target Raised to $140.00

Kymera Therapeutics (NASDAQ:KYMR) had its target price increased by Mizuho from $120.00 to $140.00 in a research report sent to investors on Thursday morning, Marketbeat Ratings reports. They currently have an outperform rating on the stock.

Several other research firms also recently weighed in on KYMR. B. Riley Financial lifted their target price on shares of Kymera Therapeutics from $117.00 to $155.00 and gave the stock a “buy” rating in a research note on Monday, June 29th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Kymera Therapeutics in a report on Tuesday, April 21st. Wall Street Zen raised shares of Kymera Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, May 2nd. Bank of America lifted their price objective on shares of Kymera Therapeutics from $110.00 to $125.00 and gave the company a “buy” rating in a research note on Tuesday, June 30th. Finally, Brookline Capital Markets reissued a “buy” rating on shares of Kymera Therapeutics in a report on Monday, June 8th. Twenty investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $122.64.

Kymera Therapeutics Stock Performance

KYMR stock opened at $115.77 on Thursday. The company has a market capitalization of $9.52 billion, a price-to-earnings ratio of -32.43 and a beta of 1.95. Kymera Therapeutics has a fifty-two week low of $36.65 and a fifty-two week high of $130.05. The stock has a fifty day moving average of $93.52 and a 200-day moving average of $85.37.

Kymera Therapeutics (NASDAQ:KYMR) last announced its quarterly earnings data on Thursday, April 30th. The company reported ($0.71) earnings per share for the quarter, topping the consensus estimate of ($0.89) by $0.18. The company had revenue of $34.37 million during the quarter, compared to analyst estimates of $8.27 million. Kymera Therapeutics had a negative return on equity of 24.71% and a negative net margin of 611.94%.The firm’s revenue for the quarter was up 55.5% on a year-over-year basis. During the same quarter last year, the firm posted ($0.82) EPS. Equities analysts predict that Kymera Therapeutics will post -3.28 EPS for the current year.

Insider Transactions at Kymera Therapeutics

In related news, Director Bruce Booth sold 31,283 shares of the business’s stock in a transaction that occurred on Monday, June 29th. The shares were sold at an average price of $109.48, for a total transaction of $3,424,862.84. Following the completion of the transaction, the director owned 461,794 shares of the company’s stock, valued at approximately $50,557,207.12. The trade was a 6.34% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Nello Mainolfi sold 50,000 shares of the company’s stock in a transaction that occurred on Tuesday, July 7th. The stock was sold at an average price of $119.00, for a total transaction of $5,950,000.00. Following the sale, the chief executive officer directly owned 666,568 shares in the company, valued at $79,321,592. This trade represents a 6.98% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders sold 3,644,113 shares of company stock valued at $390,820,176. Company insiders own 15.98% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the company. SG Americas Securities LLC grew its position in Kymera Therapeutics by 169.1% during the fourth quarter. SG Americas Securities LLC now owns 22,693 shares of the company’s stock valued at $1,766,000 after acquiring an additional 14,261 shares during the last quarter. Hudson Bay Capital Management LP grew its stake in shares of Kymera Therapeutics by 362.7% during the third quarter. Hudson Bay Capital Management LP now owns 23,134 shares of the company’s stock valued at $1,309,000 after buying an additional 18,134 shares during the last quarter. Vanguard Group Inc. grew its stake in shares of Kymera Therapeutics by 15.6% during the fourth quarter. Vanguard Group Inc. now owns 6,267,644 shares of the company’s stock valued at $487,685,000 after buying an additional 845,922 shares during the last quarter. Eagle Health Investments LP purchased a new position in shares of Kymera Therapeutics in the fourth quarter worth about $10,606,000. Finally, State of New Jersey Common Pension Fund D purchased a new position in shares of Kymera Therapeutics in the fourth quarter worth about $2,610,000.

About Kymera Therapeutics

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.